Multivalent targeting of AT₁ receptors with angiotensin II-functionalized nanoparticles

References

• Higuchi T, Fukushima K, Xia J, et al. Radionuclide imaging of angiotensin II type 1 receptor upregulation after myocardial ischemia-reperfusion injury. J Nucl Med 2010;51:1956–61
   PubMed Web of Science ®Google Scholar
• Dvir T, Bauer M, Schroeder A, et al. Nanoparticles targeting the infarcted heart. Nano Lett 2011;11:4411–14
   PubMed Web of Science ®Google Scholar
• de Paepe B, Verstraeten VL, De Potter CR, et al. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001;116:247–54
   PubMed Web of Science ®Google Scholar
• Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293–9
   PubMed Web of Science ®Google Scholar
• Nagai N, Oike Y, Izumi-Nagai K, et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularisation. Arterioscler Thromb Vasc Biol 2006;26:2252–9
   PubMed Web of Science ®Google Scholar
• Mason JN, Farmer H, Tomlinson HD, et al. Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J Neurosci Methods 2005;143:3–25
   PubMed Web of Science ®Google Scholar
• Young SH, Rozengurt E. Qdot nanocrystal conjugates conjugated to bombesin or Ang II label the cognate G protein-coupled receptor in living cells. Am J Physiol Cell Physiol 2006;290:C728–32
   Google Scholar
• Silpe JE, Sumit M, Thomas TP, et al. Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles. ACS Chem Biol 2013;8:2063–71
   PubMed Web of Science ®Google Scholar
• Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005;45:163–9
   PubMed Web of Science ®Google Scholar
• Suzuki K, Han GD, Miyauchi N, et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007;170:1841–53
   PubMed Web of Science ®Google Scholar
• Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999;10:S30–9
   Google Scholar
• Pollinger K, Hennig R, Bauer S, et al. Biodistribution of quantum dots in the kidney after intravenous injection. J Nanosci Nanotech 2014;14:3313–19
   PubMed Web of Science ®Google Scholar
• Pollinger K, Hennig R, Ohlmann A, et al. Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application. Proc Natl Acad Sci USA 2013;110:6115–20
   PubMed Web of Science ®Google Scholar
• Pollinger K, Hennig R, Breunig M, et al. Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles. Small 2012;8:3368–75
   PubMed Web of Science ®Google Scholar
• Hennig R, Pollinger K, Veser A, et al. Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation. J Control Release 2014;194C:20–7
   Web of Science ®Google Scholar
• Fierensa FL, Vanderheyden PM, Roggeman C, et al. Tight binding of the angiotensin AT1 receptor antagonist [3H]candesartan is independent of receptor internalization. Biochem Pharmacol 2001;61:1227–35
   PubMed Web of Science ®Google Scholar
• Bkaily G, Sleiman S, Stephan J, et al. Angiotensin II AT 1 receptor internalization, translocation and de novo synthesis modulate cytosolic and nuclear calcium in human vascular smooth muscle cells. Can J Physiol Pharmacol 2003;81:274–87
   PubMed Web of Science ®Google Scholar
• Wang J, Tian S, Petros RA, et al. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J Am Chem Soc 2010;132:11306–13
   PubMed Web of Science ®Google Scholar
• Banerjee D, Liu AP, Voss NR, et al. Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. ChemBioChem 2010;11:1273–9
   PubMed Web of Science ®Google Scholar
• Thomas TP, Joice M, Sumit M, et al. Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic. Curr Pharm Des 2014;19:6594–605
   Web of Science ®Google Scholar
• Tang Z, Li D, Sun H, et al. Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density. Biomaterials 2014;35:8015–27
   PubMed Web of Science ®Google Scholar
• Barua S, Yoo JW, Kolhar P, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA 2013;110:3270–5
   PubMed Web of Science ®Google Scholar
• Hendriks BS, Klinz SG, Reynolds JG, et al. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther 2013;12:1816–28
   PubMed Web of Science ®Google Scholar
• Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440–50
   PubMed Web of Science ®Google Scholar
• Hunyady L, Balla T, Catt KJ. The ligand binding site of the angiotensin AT1 receptor. Trends Pharmacol Sci 1996;17:135–40
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415–72
   PubMed Web of Science ®Google Scholar
• Mokotoff M, Mocarski YM, Gentsch BL, et al. Caution in the use of 2-iminothiolane (Traut's reagent) as a cross-linking agent for peptides. The formation of N-peptidyl-2-iminothiolanes with bombesin (BN) antagonist (d-Trp6,Leu13-psi[CH2NH]-Phe14)BN6-14 and d-Trp-Gln-Trp-NH2. J Pept Res 2001;57:383–9
   PubMedGoogle Scholar
• Singh R, Kats L, Blättler WA, Lambert JM. Formation of N-substituted 2-iminothiolanes when amino groups in proteins and peptides are modified by 2-iminothiolane. Anal Biochem 1996;236:114–25
   PubMed Web of Science ®Google Scholar
• Nishi H, Arai H, Momiyama T. NCI-H295R, a human adrenal cortex-derived cell line, expresses purinergic receptors linked to Ca2+-mobilization/influx and cortisol secretion. PLoS One 2013;8:e71022
   Google Scholar
• Huang Q, Guo Y, Zeng H, et al. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 2011;36:93–100
   PubMed Web of Science ®Google Scholar
• Mutch LJ, Howden JD, Jenner EP, et al. Polarised clathrin-mediated endocytosis of EGFR during chemotactic invasion. Traffic 2014;15:648–64
   PubMed Web of Science ®Google Scholar
• Motley A, Bright NA, Seaman MNJ, Robinson MS. Clathrin-mediated endocytosis in AP-2-depleted cells. J Cell Biol 2003;162:909–18
   PubMed Web of Science ®Google Scholar
• Iversen T-G, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 2011;6:176–85
   Web of Science ®Google Scholar
• Morinelli TA, Walker LP, Velez JCQ, Ullian ME. Clathrin-dependent internalization of the angiotensin II AT1A receptor links receptor internalization to COX-2 protein expression in rat aortic vascular smooth muscle cells. Eur J Pharmacol 2014;748C:143–8
   Google Scholar
• Hein L, Meinel L, Pratt PE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997;11:1266–77
   PubMed Web of Science ®Google Scholar
• Carpenter KA, Wilkes BC, Schiller PW. The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment. Eur J Biochem 1998;251:448–53
   PubMedGoogle Scholar
• Ji H, Leung M, Zhang Y, et al. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor: identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994;269:16533–6
   PubMed Web of Science ®Google Scholar
• Diagaradjane P, Orenstein-Cardona JM, Colón-Casasnovas NE, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731–41
   PubMed Web of Science ®Google Scholar
• Montet X, Funovics M, Montet-Abou K, et al. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 2006;49:6087–93
   PubMed Web of Science ®Google Scholar